Articles from Sana Biotechnology, Inc

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression

Fast Track designation is designed to expedite clinical development and regulatory review timelines

SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.

SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.

Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes

Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update.

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of its common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Sana. The gross proceeds from the offering were approximately $189.75 million before deducting underwriting discounts and commissions and other offering expenses.

SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions.

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares to be sold in this offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

Expect to disclose initial SC262 clinical data in 2024

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma. Treatment in this dose escalation study is ongoing, and the company expects to present more data from this study at a later date in an appropriate venue.

SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in November and December. The presentations will feature a business overview and update.

Goal is to report UP421 proof of concept data in 2023 and 2024

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases

Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 and more robust data in 2024

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.

Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer, and Nate Hardy, Sana’s Chief Financial Officer.

Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year

Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer and Nate Hardy, Sana’s Chief Financial Officer.

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on changing the possible for patients through engineered cells, today announced that management will host a Research & Development (R&D) Day on Thursday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

Hypoimmune-modified CD19-directed CAR T cells persist and remain functional in preclinical models over multiple months in an allogeneic humanized immune system, even with tumor re-challenge

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell reinjection

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system

Dr. Douglas E. Williams as Head of Research and Development

Announced SC291 IND clearance with goal to report initial clinical data this year

Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells

SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Guggenheim Healthcare Talks 5th Annual Oncology Conference at 1:00 p.m. ET on Thursday, February 9, 2023. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Goal is to report initial SC291 clinical data this year

SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems

Expect to file IND this year for SC291 with potential clinical data in 2023

SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has been named the top place to work on the BioSpace 2023 Best Places to Work small employer list.

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQSANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA.

Expect to file IND this year for SC291 with potential clinical data in 2023